Logo image of CREX

CREATIVE REALITIES INC (CREX) Stock Fundamental Analysis

NASDAQ:CREX - Nasdaq - US22530J3095 - Common Stock - Currency: USD

3.3  -0.09 (-2.65%)

After market: 3.25 -0.05 (-1.52%)

Fundamental Rating

3

CREX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 97 industry peers in the Media industry. Both the profitability and financial health of CREX have multiple concerns. CREX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

In the past year CREX was profitable.
In the past year CREX has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: CREX reported negative net income in multiple years.
In multiple years CREX reported negative operating cash flow during the last 5 years.
CREX Yearly Net Income VS EBIT VS OCF VS FCFCREX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -0.05%, CREX is in line with its industry, outperforming 56.70% of the companies in the same industry.
CREX has a Return On Equity (-0.10%) which is comparable to the rest of the industry.
With a Return On Invested Capital value of 0.43%, CREX is not doing good in the industry: 62.89% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -0.05%
ROE -0.1%
ROIC 0.43%
ROA(3y)-2.23%
ROA(5y)-17.47%
ROE(3y)-5.54%
ROE(5y)-80.4%
ROIC(3y)N/A
ROIC(5y)N/A
CREX Yearly ROA, ROE, ROICCREX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

Looking at the Operating Margin, with a value of 0.60%, CREX is doing worse than 61.86% of the companies in the same industry.
The Gross Margin of CREX (46.99%) is comparable to the rest of the industry.
CREX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.6%
PM (TTM) N/A
GM 47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.36%
GM growth 5Y1.66%
CREX Yearly Profit, Operating, Gross MarginsCREX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CREX is destroying value.
Compared to 1 year ago, CREX has more shares outstanding
Compared to 5 years ago, CREX has more shares outstanding
The debt/assets ratio for CREX is higher compared to a year ago.
CREX Yearly Shares OutstandingCREX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CREX Yearly Total Debt VS Total AssetsCREX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 0.23, we must say that CREX is in the distress zone and has some risk of bankruptcy.
CREX has a worse Altman-Z score (0.23) than 65.98% of its industry peers.
CREX has a Debt/Equity ratio of 0.78. This is a neutral value indicating CREX is somewhat dependend on debt financing.
CREX has a Debt to Equity ratio (0.78) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z 0.23
ROIC/WACC0.06
WACC7.45%
CREX Yearly LT Debt VS Equity VS FCFCREX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

CREX has a Current Ratio of 1.23. This is a normal value and indicates that CREX is financially healthy and should not expect problems in meeting its short term obligations.
CREX has a Current ratio of 1.23. This is comparable to the rest of the industry: CREX outperforms 42.27% of its industry peers.
CREX has a Quick Ratio of 1.10. This is a normal value and indicates that CREX is financially healthy and should not expect problems in meeting its short term obligations.
CREX has a worse Quick ratio (1.10) than 61.86% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.1
CREX Yearly Current Assets VS Current LiabilitesCREX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 309.09% over the past year.
CREX shows a small growth in Revenue. In the last year, the Revenue has grown by 1.67%.
The Revenue has been growing by 9.98% on average over the past years. This is quite good.
EPS 1Y (TTM)309.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7900%
Revenue 1Y (TTM)1.67%
Revenue growth 3Y40.23%
Revenue growth 5Y9.98%
Sales Q2Q%-20.77%

3.2 Future

The Earnings Per Share is expected to grow by 73.78% on average over the next years. This is a very strong growth
CREX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.96% yearly.
EPS Next Y181.91%
EPS Next 2Y73.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.28%
Revenue Next 2Y13.96%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CREX Yearly Revenue VS EstimatesCREX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
CREX Yearly EPS VS EstimatesCREX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 7.17, the valuation of CREX can be described as very cheap.
CREX's Price/Earnings ratio is rather cheap when compared to the industry. CREX is cheaper than 86.60% of the companies in the same industry.
CREX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.45.
CREX is valuated reasonably with a Price/Forward Earnings ratio of 9.80.
CREX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CREX is cheaper than 74.23% of the companies in the same industry.
CREX is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.90, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 7.17
Fwd PE 9.8
CREX Price Earnings VS Forward Price EarningsCREX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CREX is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11.96
CREX Per share dataCREX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CREX's earnings are expected to grow with 73.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y73.78%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

CREX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CREATIVE REALITIES INC

NASDAQ:CREX (7/3/2025, 7:14:02 PM)

After market: 3.25 -0.05 (-1.52%)

3.3

-0.09 (-2.65%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners18.11%
Inst Owner Change-8.75%
Ins Owners16.42%
Ins Owner Change4.94%
Market Cap34.72M
Analysts84
Price Target5.61 (70%)
Short Float %1.07%
Short Ratio0.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)230.68%
Min EPS beat(2)-140.1%
Max EPS beat(2)601.45%
EPS beat(4)3
Avg EPS beat(4)160.43%
Min EPS beat(4)-140.1%
Max EPS beat(4)601.45%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.64%
Min Revenue beat(2)-11.52%
Max Revenue beat(2)4.23%
Revenue beat(4)3
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-11.52%
Max Revenue beat(4)4.23%
Revenue beat(8)3
Avg Revenue beat(8)-4.2%
Revenue beat(12)3
Avg Revenue beat(12)-4.26%
Revenue beat(16)3
Avg Revenue beat(16)-3.68%
PT rev (1m)-16.98%
PT rev (3m)-24.14%
EPS NQ rev (1m)-9.53%
EPS NQ rev (3m)-291.67%
EPS NY rev (1m)221.84%
EPS NY rev (3m)130.44%
Revenue NQ rev (1m)-1.37%
Revenue NQ rev (3m)-22.61%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-7.06%
Valuation
Industry RankSector Rank
PE 7.17
Fwd PE 9.8
P/S 0.72
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB N/A
EV/EBITDA 11.96
EPS(TTM)0.46
EY13.94%
EPS(NY)0.34
Fwd EY10.2%
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS4.59
BVpS2.84
TBVpS-1.8
PEG (NY)0.04
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.05%
ROE -0.1%
ROCE 0.55%
ROIC 0.43%
ROICexc 0.44%
ROICexgc 6.2%
OM 0.6%
PM (TTM) N/A
GM 47%
FCFM N/A
ROA(3y)-2.23%
ROA(5y)-17.47%
ROE(3y)-5.54%
ROE(5y)-80.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.36%
GM growth 5Y1.66%
F-Score3
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA 4.93
Cap/Depr 58.56%
Cap/Sales 5.37%
Interest Coverage 0.26
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.1
Altman-Z 0.23
F-Score3
WACC7.45%
ROIC/WACC0.06
Cap/Depr(3y)115.1%
Cap/Depr(5y)95.1%
Cap/Sales(3y)8.11%
Cap/Sales(5y)6.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)309.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7900%
EPS Next Y181.91%
EPS Next 2Y73.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.67%
Revenue growth 3Y40.23%
Revenue growth 5Y9.98%
Sales Q2Q%-20.77%
Revenue Next Year9.28%
Revenue Next 2Y13.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-78.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year709.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-40%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-151.33%
OCF growth 3Y93.04%
OCF growth 5YN/A